Search Within

Briana R Cadzin

Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (7)
  2. Department of Medicine (7)
  3. Hematologic Malignancies, Division of (7)
  4. Adult Leukemia (6)
  5. Bone Marrow Transplant (6)
  6. GME, Medicine (4)

More Groups

People
  1. Jae Park (4)
  2. Maria Palomba (4)
  3. Mark Geyer (4)
  4. Brigitte Senechal (3)
  5. Elizabeth Cathcart (3)
  6. Gunjan Shah (3)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2022 (2)
  4. 2021 (1)
  5. 2017 (1)
Publications
  1. Blood (5)
  2. JAMA Oncology (1)
  3. New England Journal of Medicine (1)
Publishers
  1. American Society of Hematology (5)
  2. American Medical Association (1)
  3. Massachusetts Medical Society (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Barriers to chimeric antigen receptor T-cell therapy
    Research Letter

    Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • CD371-targeted CAR T-cells secreting interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia
    Meeting Abstract

    Geyer, M. B.; Dewolf, S.; Mi, X.; Shaffer, B. C.; Cadzin, B.; McAvoy, D.; Hosszu, K. K.; Weis, K.; Lorenc, R.; Lewis, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
    Blood (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save